U.S. Markets open in 42 mins

Alnylam Pharmaceuticals (NASDAQ:ALNY) Is In A Strong Position To Grow Its Business

Simply Wall St

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

Given this risk, we thought we'd take a look at whether Alnylam Pharmaceuticals (NASDAQ:ALNY) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

Check out our latest analysis for Alnylam Pharmaceuticals

How Long Is Alnylam Pharmaceuticals's Cash Runway?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When Alnylam Pharmaceuticals last reported its balance sheet in September 2019, it had zero debt and cash worth US$1.7b. In the last year, its cash burn was US$372m. Therefore, from September 2019 it had 4.6 years of cash runway. Importantly, though, analysts think that Alnylam Pharmaceuticals will reach cashflow breakeven before then. In that case, it may never reach the end of its cash runway. You can see how its cash balance has changed over time in the image below.

NasdaqGS:ALNY Historical Debt, December 2nd 2019

How Well Is Alnylam Pharmaceuticals Growing?

We reckon the fact that Alnylam Pharmaceuticals managed to shrink its cash burn by 41% over the last year is rather encouraging. Having said that, the revenue growth of 84% was considerably more inspiring. It seems to be growing nicely. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

Can Alnylam Pharmaceuticals Raise More Cash Easily?

There's no doubt Alnylam Pharmaceuticals seems to be in a fairly good position, when it comes to managing its cash burn, but even if it's only hypothetical, it's always worth asking how easily it could raise more money to fund growth. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash to drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Alnylam Pharmaceuticals's cash burn of US$372m is about 2.8% of its US$13b market capitalisation. So it could almost certainly just borrow a little to fund another year's growth, or else easily raise the cash by issuing a few shares.

Is Alnylam Pharmaceuticals's Cash Burn A Worry?

It may already be apparent to you that we're relatively comfortable with the way Alnylam Pharmaceuticals is burning through its cash. For example, we think its revenue growth suggests that the company is on a good path. Its cash burn reduction wasn't quite as good, but was still rather encouraging! Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. After considering a range of factors in this article, we're pretty relaxed about its cash burn, since the company seems to be in a good position to continue to fund its growth. We think it's very important to consider the cash burn for loss making companies, but other considerations such as the amount the CEO is paid can also enhance your understanding of the business. You can click here to see what Alnylam Pharmaceuticals's CEO gets paid each year.

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.